All In Biotech

Drug Trial Radar · NCT05605093

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

602

Actual

Start

Dec 23, 2022

Primary completion

Oct 28, 2025

Study completion Oct 28, 2025

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Nov 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.

Conditions

  • COVID-19

Interventions

  • Shionogi Protease Inhibitor (S-217622)Drug

    S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).

  • placeboDrug

    Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Recovered by Day 60Time frame: Through Day 60

Locations

187 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham University Hospital (Site 213-002)

    Birmingham, Alabama

  • Banner University Medical Center Tucson (Site 206-004)

    Tucson, Arizona

  • Southern Arizona VA Healthcare System (Site 074-009)

    Tucson, Arizona

  • UCSF Fresno (Site 203-005)

    Fresno, California

  • VA Loma Linda Healthcare System (Site 074-017)

    Loma Linda, California

  • MemorialCare Health System (Site 066-003

    Long Beach, California

  • VA Long Beach Healthcare System (Site 074-026)

    Long Beach, California

  • Cedars-Sinai Medical Center (Site 208-002)

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center (Site 203-002)

    Los Angeles, California

  • VA Northern California Health Care System (Site 074-023)

    Mather, California

  • Hoag Memorial Hospital Presbyterian (Site 080-026)

    Newport Beach, California

  • Veterans Affairs Palo Alto Health Care System (VAPAHCS) (Site 074-005)

    Palo Alto, California

  • UC Davis Health (Site 203-004)

    Sacramento, California

  • VA San Diego Healthcare System (Site 074-016)

    San Diego, California

  • Zuckerberg San Francisco General Hospital and Trauma Center (Site 213-007)

    San Francisco, California

  • UCSF Medical Center at Mount Zion (203-007)

    San Francisco, California

  • San Francisco VAMC (Site 074-002)

    San Francisco, California

  • University of California San Francisco (Site 203-001)

    San Francisco, California

  • Stanford University Hospital & Clinics (Site 203-003)

    Stanford, California

  • Lundquist Institute for Biomedical Innovation (Site 066-002)

    Torrance, California

  • Rocky Mountain Regional VA Medical Center (Site 074-010)

    Aurora, Colorado

  • University of Colorado Hospital (Site 204-001)

    Aurora, Colorado

  • Public Health Institute at Denver Health (Site 017-004)

    Denver, Colorado

  • Yale University (Site 025-001)

    New Haven, Connecticut

  • MedStar Health Research Institute/MedStar Washington Hospital Center (Site 009-021)

    Washington D.C., District of Columbia

  • Washington DC VA Medical Center (Site 009-004)

    Washington D.C., District of Columbia

  • University of Florida - Gainesville (Site 201-004)

    Gainesville, Florida

  • Miami VA Healthcare System (Site 074-003)

    Miami, Florida

  • Orlando VA Medical Center (Site 074-032)

    Orlando, Florida

  • Tampa General Hospital (032-001)

    Tampa, Florida

  • John H. Stroger, Jr. Hospital of Cook County (Site 080-046)

    Chicago, Illinois

  • University of Illinois at Chicago (Site 008-012)

    Chicago, Illinois

  • Carle Foundation Hospital (Site 080-049)

    Urbana, Illinois

  • Lutheran Medical Group (Site 301-010)

    Fort Wayne, Indiana

  • The University of Kansas Hospital (Site 080-044)

    Kansas City, Kansas

  • University of Kentucky (Site 210-004)

    Lexington, Kentucky

  • NIH Clinical Center (Site 080-043)

    Bethesda, Maryland

  • Massachusetts General Hospital (202-002)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center (Site 202-001)

    Boston, Massachusetts

  • Baystate Medical Center (Site 201-001)

    Springfield, Massachusetts

Showing 40 of 187 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.